4//SEC Filing
McClung David Mark 4
Accession 0001209191-21-043811
CIK 0001001233other
Filed
Jun 28, 8:00 PM ET
Accepted
Jun 29, 7:55 PM ET
Size
6.0 KB
Accession
0001209191-21-043811
Insider Transaction Report
Form 4
McClung David Mark
EVP Chief Business Officer
Transactions
- Tax Payment
Common Stock
2021-06-25$12.02/sh−11,525$138,531→ 129,294 total
Footnotes (2)
- [F1]Represents shares underlying the portion of restricted stock unit ("RSU") grant that vested on June 25, 2021 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on June 25, 2021 of $12.02/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended").
- [F2]Includes: (a) 21,805 shares resulting from the June 25, 2021 vesting of the Reporting Person's June 25, 2020 RSU grant and 66,670 shares subject to such RSU grant that will vest in two remaining annual installments on June 25, 2022 and June 25, 2023; (b) 40,000 shares subject to a grant of RSUs to the Reporting Person on February 25, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date. The vesting of all such RSUs is subject to the Reporting Person's continued service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended; and (3) 819 shares acquired by the Reporting Person on May 28, 2021 under the Issuer's 2020 Employee Stock Purchase Plan.
Documents
Issuer
SANGAMO THERAPEUTICS, INC
CIK 0001001233
Entity typeother
Related Parties
1- filerCIK 0001811505
Filing Metadata
- Form type
- 4
- Filed
- Jun 28, 8:00 PM ET
- Accepted
- Jun 29, 7:55 PM ET
- Size
- 6.0 KB